Aarey Drugs & Pharmaceuticals Receives 'Hold' Rating After Positive Financial Results

May 21 2024 07:08 PM IST
share
Share Via
Aarey Drugs & Pharmaceuticals, a microcap company in the trading industry, has received a 'Hold' rating from MarketsMojo after declaring positive results in December 2023. Its net sales and PBDIT have shown significant growth, contributing to the rating. The stock has also outperformed the market in the past year, but its long-term fundamental strength is weak. Investors should carefully consider these factors before investing.
Aarey Drugs & Pharmaceuticals, a microcap company in the trading industry, has recently received a 'Hold' rating from MarketsMOJO on May 21, 2024. This upgrade comes after the company declared positive results in December 2023, breaking a streak of 7 consecutive negative quarters.

The company's net sales for the quarter have shown a growth of 22.43%, reaching Rs 76.48 crore. Additionally, its PBDIT for the quarter has also reached its highest at Rs 2.71 crore, with operating profit to net sales ratio at 3.54%. These positive financial indicators have contributed to the 'Hold' rating.

Technically, the stock is currently in a mildly bullish range, with an improved trend from sideways on May 14, 2024. Since then, the stock has generated a return of -2.08%. The MACD and KST technical factors also show a bullish trend.

With a ROCE of 2.3, the stock is considered to have an attractive valuation, with an enterprise value to capital employed ratio of 1.1. It is also trading at a discount compared to its average historical valuations. In the past year, the stock has generated a return of 81.66%, while its profits have risen by 59.3%. The PEG ratio of the company stands at 0.5.

The majority shareholders of Aarey Drugs & Pharmaceuticals are the promoters, indicating their confidence in the company's performance. The stock has also outperformed the market (BSE 500) with a return of 81.66% in the last year, compared to the market's return of 36.54%.

However, the company's long-term fundamental strength is weak, with a -38.02% CAGR growth in operating profits over the last 5 years. The return on equity (average) is also low at 6.74%, indicating low profitability per unit of shareholders' funds.

Overall, Aarey Drugs & Pharmaceuticals has shown positive growth in its recent financial results, leading to a 'Hold' rating from MarketsMOJO. While the stock has outperformed the market in the past year, its long-term fundamental strength is weak. Investors are advised to carefully consider these factors before making any investment decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News